Leerink Partnrs Analysts Lower Earnings Estimates for SCPH

scPharmaceuticals Inc. (NASDAQ:SCPH) – Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings estimates for shares of scPharmaceuticals in a research report issued on Wednesday, May 14th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn ($0.37) per share for the quarter, down from their previous forecast of ($0.31). The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.53) per share. Leerink Partnrs also issued estimates for scPharmaceuticals’ Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($0.70) EPS.

Several other equities research analysts have also issued reports on the stock. Maxim Group reduced their target price on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a report on Thursday, March 20th.

scPharmaceuticals Trading Up 11.8%

scPharmaceuticals stock opened at $3.22 on Monday. The firm has a 50 day moving average of $2.60 and a 200 day moving average of $3.16. The firm has a market capitalization of $169.99 million, a price-to-earnings ratio of -1.69 and a beta of 0.17. scPharmaceuticals has a 12-month low of $1.94 and a 12-month high of $5.65. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66.

scPharmaceuticals (NASDAQ:SCPH) last released its earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The firm had revenue of $11.75 million during the quarter, compared to analysts’ expectations of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC bought a new position in scPharmaceuticals in the 1st quarter worth approximately $76,000. Apis Capital Advisors LLC boosted its stake in scPharmaceuticals by 28.2% in the 1st quarter. Apis Capital Advisors LLC now owns 504,947 shares of the company’s stock worth $1,328,000 after purchasing an additional 110,947 shares during the period. Kingdon Capital Management L.L.C. boosted its stake in scPharmaceuticals by 25.0% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,000,000 shares of the company’s stock worth $2,630,000 after purchasing an additional 200,000 shares during the period. Velan Capital Investment Management LP bought a new position in scPharmaceuticals in the 1st quarter worth approximately $2,413,000. Finally, Comerica Bank boosted its stake in scPharmaceuticals by 22.1% in the 1st quarter. Comerica Bank now owns 38,662 shares of the company’s stock worth $102,000 after purchasing an additional 7,000 shares during the period. 89.52% of the stock is currently owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.